Panagene Inc
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more
Panagene Inc (046210) - Net Assets
Latest net assets as of September 2025: ₩77.27 Billion KRW
Based on the latest financial reports, Panagene Inc (046210) has net assets worth ₩77.27 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩101.91 Billion) and total liabilities (₩24.65 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩77.27 Billion |
| % of Total Assets | 75.81% |
| Annual Growth Rate | 9.35% |
| 5-Year Change | 203.32% |
| 10-Year Change | 753.8% |
| Growth Volatility | 50.5 |
Panagene Inc - Net Assets Trend (2005–2024)
This chart illustrates how Panagene Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Panagene Inc (2005–2024)
The table below shows the annual net assets of Panagene Inc from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩76.04 Billion | +19.62% |
| 2023-12-31 | ₩63.57 Billion | +100.61% |
| 2022-12-31 | ₩31.69 Billion | +6.18% |
| 2021-12-31 | ₩29.84 Billion | +19.04% |
| 2020-12-31 | ₩25.07 Billion | +24.08% |
| 2019-12-31 | ₩20.20 Billion | +23.93% |
| 2018-12-31 | ₩16.30 Billion | -17.82% |
| 2017-12-31 | ₩19.84 Billion | -5.97% |
| 2016-12-31 | ₩21.10 Billion | +136.88% |
| 2015-12-31 | ₩8.91 Billion | -0.19% |
| 2012-12-31 | ₩8.92 Billion | -44.01% |
| 2011-12-31 | ₩15.94 Billion | -4.36% |
| 2010-12-31 | ₩16.66 Billion | -7.03% |
| 2009-12-31 | ₩17.92 Billion | -30.75% |
| 2008-12-31 | ₩25.88 Billion | -24.18% |
| 2007-12-31 | ₩34.14 Billion | +10.35% |
| 2006-12-31 | ₩30.94 Billion | +122.13% |
| 2005-12-31 | ₩13.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Panagene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6103827490000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩21.25 Billion | 27.95% |
| Other Components | ₩115.83 Billion | 152.32% |
| Total Equity | ₩76.04 Billion | 100.00% |
Panagene Inc Competitors by Market Cap
The table below lists competitors of Panagene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Caprice Resources Limited
F:C3F
|
$29.97 Million |
|
Acrinova AB Series B
ST:ACRI-B
|
$29.98 Million |
|
Romsdal Sparebank
OL:ROMSB
|
$30.01 Million |
|
Bo Lak
KO:002760
|
$30.02 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
$29.95 Million |
|
European Lithium Limited
OTCQB:EULIF
|
$29.94 Million |
|
HI SPAC 3
KQ:217500
|
$29.94 Million |
|
Tainet Communication System
TWO:4905
|
$29.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Panagene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 63,572,923,440 to 76,043,116,760, a change of 12,470,193,320 (19.6%).
- Net loss of 1,943,932,240 reduced equity.
- Share repurchases of 38,390,000 reduced equity.
- New share issuances of 38,390,000 increased equity.
- Other factors increased equity by 14,414,125,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.94 Billion | -2.56% |
| Share Repurchases | ₩38.39 Million | -0.05% |
| Share Issuances | ₩38.39 Million | +0.05% |
| Other Changes | ₩14.41 Billion | +18.96% |
| Total Change | ₩- | 19.62% |
Book Value vs Market Value Analysis
This analysis compares Panagene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.17x to 1.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩710.77 | ₩2250.00 | x |
| 2017-12-31 | ₩621.08 | ₩2250.00 | x |
| 2018-12-31 | ₩508.94 | ₩2250.00 | x |
| 2019-12-31 | ₩628.71 | ₩2250.00 | x |
| 2020-12-31 | ₩780.11 | ₩2250.00 | x |
| 2021-12-31 | ₩928.65 | ₩2250.00 | x |
| 2022-12-31 | ₩986.08 | ₩2250.00 | x |
| 2023-12-31 | ₩1550.39 | ₩2250.00 | x |
| 2024-12-31 | ₩1788.94 | ₩2250.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Panagene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.73%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.44x
- Recent ROE (-2.56%) is above the historical average (-15.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -74.89% | -41.50% | 0.98x | 1.84x | ₩-15.22 Billion |
| 2010 | -24.25% | -11.87% | 0.89x | 2.30x | ₩-5.71 Billion |
| 2011 | -9.99% | -3.84% | 0.98x | 2.66x | ₩-3.19 Billion |
| 2012 | -83.36% | -25.97% | 1.12x | 2.86x | ₩-8.33 Billion |
| 2015 | -7.07% | -10.64% | 0.23x | 2.88x | ₩-1.52 Billion |
| 2016 | -7.38% | -22.38% | 0.21x | 1.57x | ₩-3.67 Billion |
| 2017 | -35.08% | -94.11% | 0.27x | 1.41x | ₩-8.94 Billion |
| 2018 | -25.26% | -53.46% | 0.32x | 1.48x | ₩-5.75 Billion |
| 2019 | 17.35% | 44.09% | 0.36x | 1.08x | ₩1.48 Billion |
| 2020 | 19.61% | 30.22% | 0.60x | 1.09x | ₩2.41 Billion |
| 2021 | 16.64% | 31.84% | 0.49x | 1.07x | ₩1.98 Billion |
| 2022 | 7.07% | 15.81% | 0.41x | 1.09x | ₩-928.43 Million |
| 2023 | -7.57% | -39.30% | 0.13x | 1.43x | ₩-11.17 Billion |
| 2024 | -2.56% | -14.73% | 0.12x | 1.44x | ₩-9.55 Billion |
Industry Comparison
This section compares Panagene Inc's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $64,687,642,895
- Average return on equity (ROE) among peers: -10.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Panagene Inc (046210) | ₩77.27 Billion | -74.89% | 0.32x | $29.96 Million |
| Macrogen Inc (038290) | $118.01 Billion | 2.24% | 0.52x | $99.40 Million |
| Cell Biotech Co. Ltd (049960) | $52.36 Billion | 19.87% | 0.10x | $43.10 Million |
| Bioneer Corporation (064550) | $26.11 Billion | -55.21% | 1.44x | $175.97 Million |
| MEDIPOST Co. Ltd (078160) | $143.31 Billion | -3.74% | 0.25x | $192.41 Million |
| Biotoxtech Co. Ltd (086040) | $41.14 Billion | 17.29% | 1.21x | $23.35 Million |
| Peptron Inc (087010) | $7.18 Billion | -42.42% | 0.61x | $3.92 Billion |